Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Lyell Immunopharma, Inc

Contributing Author

Recent Articles by Lyell Immunopharma, Inc

Sep-14
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference LYEL -5.27% GlobeNewswire
Sep-10
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer LYEL -5.28% GlobeNewswire
Aug-06
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 LYEL +5.65% GlobeNewswire
Jun-25
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference LYEL GlobeNewswire
Jun-12
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress LYEL GlobeNewswire
Jun-08
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion LYEL GlobeNewswire
Jun-04
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress LYEL LYEL -8.28% GlobeNewswire
Jun-01
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 LYEL GlobeNewswire
May-12
Lyell Immunopharma Announces Participation in May Investor Conferences LYEL GlobeNewswire
May-06
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 LYEL GlobeNewswire
Apr-07
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference LYEL GlobeNewswire
Mar-12
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results LYEL LYEL -14.23% GlobeNewswire
Mar-09
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer LYEL +13.54% GlobeNewswire
Feb-23
Lyell Immunopharma Announces Participation in March Investor Conferences LYEL +6.12% GlobeNewswire
Feb-12
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma LYEL GlobeNewswire
Dec-07
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition LYEL GlobeNewswire
Nov-12
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 LYEL GlobeNewswire
Nov-10
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer LYEL GlobeNewswire
Nov-03
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition LYEL GlobeNewswire
Sep-03
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee LYEL GlobeNewswire
Sep-02
Lyell Immunopharma Announces Participation in September Investor Conferences LYEL GlobeNewswire
Aug-12
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 LYEL GlobeNewswire
Jul-25
Lyell Immunopharma Announces up to $100 Million Equity Private Placement LYEL +19.31% GlobeNewswire
Jun-23
Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series LYEL LYEL +6.62% GlobeNewswire
Jun-17
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma LYEL GlobeNewswire
Jun-09
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments LYEL LYEL -13.39% GlobeNewswire
Jun-04
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference LYEL +68.59% LYEL -14.92% GlobeNewswire
May-13
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 LYEL GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)